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The concept of personalized medicine not only promises to enhance the life of patients and increase the quality of
clinical practice and targeted care pathways, but also to lower overall healthcare costs through early-detection,
prevention, accurate risk assessments and efficiencies in care delivery. Current inefficiencies are widely regarded as
substantial enough to have a significant impact on the economies of major nations like the US and China, and,
therefore the world economy. A recent OECD report estimates healthcare expenditure for some of the developed
western and eastern nations to be anywhere from 10% to 18%, and growing (with the US at the highest).
Personalized medicine aims to use state-of-the-art genomic technologies, rich medical record data, tissue and
blood banks and clinical knowledge that will allow clinicians and payors to tailor treatments to individuals, thereby
greatly reducing the costs of ineffective therapies incurred through the current trial and error clinical paradigm.
Pivotal to the field are drugs that have been designed to target a specific molecular pathway that has gone wrong
and results in a diseased condition and the diagnostic tests that allow clinicians to separate responders from
non-responders. However, the truly personalized approach in medicine faces two major problems: complex biology
and complex economics; the pathways involved in diseases are quite often not well understood, and most targeted
drugs are very expensive. As a result of all current efforts to translate the concepts of personalized healthcare into
the clinic, personalized medicine becomes participatory and this implies patient decisions about their own health.
Such a new paradigm requires powerful tools to handle significant amounts of personal information with the
approach to be known as “P4 medicine”, that is predictive, preventive, personalized and participatory. P4 medicine
promises to increase the quality of clinical care and treatments and will ultimately save costs. The greatest
challenges are economic, not scientific.
Keywords: Clinical practice, Companion & molecular diagnostics, Healthcare, Incentives, Personalized medicine,
Translational genomicsPersonalized medicine
Avoiding trial and error phases through better and truly
personalized medicine, using genetic profiles to identify
the best possible drug and therapy for a given patient and
reducing adverse effects, are among the key personalized
medicine goals that will benefit not only patients, but
healthcare systems in general. The P4 medical approach,
predictive, preventive, personalized and participatory
medicine, will help to identify the right drug for the
right patient at the right time, avoiding the prescription of
costly and ineffective drugs and preventing potentially* Correspondence: rossbachm@gis.a-star.edu.sg
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reproduction in any medium, provided the origharmful side-effects (Figure 1). In this regard, P4 medicine
describes a systems approach to medicine that includes
the aforementioned four aspects and several factors fuel
this development, viz. (i) the appreciation that medicine
is a knowledge-based, information science, (ii) systems
approaches are inextricably linked with studying the
tremendous complexity of diseases and disease analysis,
(iii) new computational and mathematical methods will
allow for the analysis of thousands of data points associ-
ated with each individual patient. Particularly, novel
genome-based diagnostic technologies represent a signifi-
cant advance in medical practice in comparison with the
current prevention methods; a combination of genetic
knowledge and clinical studies is expected to impart a
significant advance toward preventive medicine and,This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Figure 1 Better patient treatments through advanced diagnostics and personalized medicine. Diagnostic tests will guide the clinical
decision-making to prescribe a specific drug, depending on the patient’s prognosis to be a responder or non-responder to a given medication
(VFA Bio).
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hurdle in this regard is that the developers of novel
molecular diagnostics are not well aligned with the
pharmaceutical manufacturers whose products might be
affected by the knowledge gained from the diagnostics.
We are in a great need of much broader and better
collaborations between the diagnostic test developers,
who are focusing on the targeting early drug develop-
ment efforts and the pharmaceutical companies that
manufacture and sell the drugs.
Rapid advances in electronic medical record systems
utilized by patient care providers is showing an enor-
mous opportunity to deliver efficiencies in retrieving,
updating and providing real time access to individualized
patient records in a wide variety of circumstances (battle-
fields, travel situations, emergency rooms, etc.). Such real-
time medical record systems will provide state of the art
data about patient responsiveness to therapies in specific
disease states (including up to date information on thera-
peutics and treatments by responder category), and enable
cost-effective treatments and personalized care pathways.
In a third category, biomarker-based diagnostics have a
significant impact on the development of both therapeutic
and diagnostic agents, a concept known as theranostics
and are highly relevant for drug development and future
personalized medicine. At present, one can identify several
different models for such future medicines, viz. (i) drugs
for a certain phenotype, (ii) drugs for a very small and
specific patient population, and (iii) one drug for one
patient, which is the classic and original idea of person-
alized medicine, implying the development of a targeted
therapy for each and every individual patient. For all
models, the overall personalized medicine structure
needs a closer coordination among researchers, clini-
cians, manufacturers, and payors. P4 medicine could
mature as the idea of consumer-driven healthcareadvances with a strong focus on individual health needs,
and on concentrating more on preventive care, rather
than on treatments and resultant expenditures once a
disease has emerged.
The new theranostics paradigm is the key to truly
private and personalized medicine, a tailored approach to
a patient’s treatment and outcome based on the molecular
analysis of the genome. This approach attracted a lot of
attention in the biomedical and clinical field and generated
much excitement in recent years; however, so far, only a
few personalized medicine based diagnostic tests have
achieved high levels of clinical adoption. It is estimated
that nearly 30-40% of patients get ineffective drugs (where
the costs arising from adverse events and toxicities out-
weigh the benefits). Theranostics can cut down the false-
positive rates tremendously and improve upon targeted
therapy. Currently 20% of the Pharma R&D is gene-based,
and this is increasingly showing promise in identifying
novel therapies at a fraction of the costs of the complex
clinical trials processes.
Aligning incentives? Challenges!
En route to clinical practice of personalized medicine,
several challenges remain, among them scientific ones, i.e.
a poor understanding of the underlying pathways and mo-
lecular networks in various, particularly complex diseases,
and a lack of biomarkers associated with some diseases
and practical ones, a lack of the tools that could speed the
mining of reams of data for clinically significant meaning,
and the lack of access to current tools to access and utilize
existing data (Garcia Martinez de Lecea, 2012).
Although the challenges in each of these areas are
significant, a consistent factor among all three is that the
operational and economic challenges seem to be the
major hindrances. Often, operational challenges can be
resolved within a particular stakeholder group, whereas
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benefits to efficiency incentives are more complex and
more difficult to be resolved. For example, a medical
treatment paradigm that rewards clinicians (in terms of
economic gain) for foregoing medical tests the same
time outcomes are typically enhanced by greater testing,
is solved the moment that costs for testing or technologies
that limit the need for testing in certain subpopulations is
introduced. In contrast to the promise of personalized
healthcare to dramatically reduce costs, most payers have
been slow in investing in personalized healthcare. Reasons
are numerous, and include the following: (i) it is difficult
to identify, which diagnostic tests, corresponding assays,
information technologies and operational systems will
truly save costs; (ii) although individual diagnostic tests or
systems may not be very expensive, the overall costs could
be amazingly high; (iii) data security is a very challenging
task as private information must be protected, particularly
in the stages of investigation and development; (iv)
establishing standards in healthcare has always been very
challenging; and (v) no structures exist that allow payers
to assess cost savings from prognostic and preventive
diagnostic testing. However, diagnostic tests tailored to a
patient’s conditions, comorbidities, medical record infor-
mation, including past history of medications may help to
avoid expensive therapies, such as chemotherapies in can-
cer treatment, and significantly minimize costly adverse
procedures. Companion diagnostic assays for Herceptin
treatment is a good example of the value provided in
predictive tests prior to prescribing the treatment regimen.
As such, novel diagnostics and healthcare information
technology (Health-IT) tools and systems have the poten-
tial of being cost effective for payers and providers. In con-
trast, diagnostics that save only small amounts per patient
or have a low probability of identifying patients requiring
intervention are not very cost effective.
Furthermore, the high customer turnover of many
commercial payers makes it less attractive for payers to
reimburse prophylactic tests that minimize the likelihood
of a disease occurring much later in life. Also, to differen-
tiate between a diagnostic test that actually saves costs on
a long-term basis and tests that create costs, it may be in
the interests of payers to delay adopting novel biomarker-
based diagnostics since actual cost savings of such tests
may not be known until a test has been on the market for
some time. Consequently, the generation of high-quality
health economics evidence could provide a basis and the
confidence that enables payers to faster adopt diagnostic
tests and would align physicians’ incentives with patient
care, clinical practice and outcomes. In this sense, such
developments could create a source of competitive advan-
tage for payers that become better at identifying and
implementing policies to promote cost-saving novel diag-
nostics. Another challenge is the current procedure-basedreimbursement system for providers in many countries;
physicians could be more likely to perform tests that in-
crease the number of procedures performed than tests
that reduce the number of procedures due to their finan-
cial interests. Also, diagnostic tests could identify a lot
more patients of a certain risk for a specific disease, like
cancer, which would align very well with economic inter-
ests of oncologists, for instance, whereas other tests may
be cost neutral or have microeconomic disincentives.
In the future, a patient will be surrounded by a huge
amount of data points that uniquely define the individual
medical history and will reflect the current health status
(Figure 2).
Mining such data will help to generate computational
methods and algorithms to predict future clinical needs
for each patient and to generate comprehensive profiles
of patient groups. Such stratified patient populations
and comprehensive systems biology approaches will
result in powerful new diagnostics and therapeutics and
provide invaluable new insights into prevention. Key to
these developments will be the integration of medical
data in the context of the dynamic biological pathways
and molecular networks in both health and disease that
are both actionable and predictive and thus useful to
both clinicians and patients.
Economic considerations
Generally speaking, the challenge is to find the balance
between the patient’s benefit, economic value and clin-
ical merit for biomarker-based diagnostics. Pharmaceut-
ical companies are beginning to focus more on such
biomarker-based diagnostics that come along with com-
panion diagnostic tests that identify a patient’s likelihood
of responding to a drug or experiencing side effects (toxic-
ities) and are intended to assist physicians in making treat-
ment decisions for their patients. The two main groups of
companion diagnostics include (i) tests that have been
developed after a drug has come to market and (ii) tests
that are being developed in conjunction, as a companion,
to the drug. Today, a majority of drugs in developmental
pipeline come along with associated biomarker programs,
with the number likely to be increasing. Such companion
diagnostic tests can improve research productivity by
decreasing trial sizes, increasing the speed to market and
supporting higher drug prices. Companion diagnostics
have the potential to significantly influence drug develop-
ment and the commercialization of lead candidates
through safer drugs with enhanced therapeutic efficacy.
Today, knowledge about the molecular mechanisms and
pathways a drug interferes with gained through next-
generation genomic technologies is crucial for drug devel-
opers before clinical symptoms are studied in clinical
trials. Such genomic technologies identify biomarkers that
are qualified to be used as diagnostic and prognostic
Figure 2 Personalized healthcare, stakeholder space.
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diagnostics are rapidly evolving as many pharmaceutical
companies focus on the development of targeted therapies
and consider the benefits for a diagnostic test to pair with
a specific treatment. Such tests are showing potential in
reducing tremendously the costs of clinical trials (close to
2/3rds of the clinical trial costs in some cases). A recent
report estimates over 130 million in savings for pharma
companies per approved compound. Unfortunately, scien-
tific and clinical factors place limits on the pace of such
developments. For many pathophysiological conditions,
the underlying principles are far from being understood or
the current scientific knowledge is insufficient to select for
specific biomarkers at early stages of a disease. In other
areas, there is no immediate clinical need for companion
diagnostics. It seems that, in general, the potential to
generate a greater value after market launch, through
increasing market shares, is much more important for the
economics of pharmaceutical and biomedical companies
than making development more productive, and compan-
ion diagnostics may not contribute a lot to improve devel-
opment productivity. Actually, they might even increase
overall costs and delay drug developments since clinical
trials must frequently be larger when companion diagnos-
tics are employed and candidate biomarkers must be
tested if it is unclear, which markers will be predictive.
Further, regulatory authorities require marker-negative pa-
tients to be included in clinical trials. Moreover, decision
analysis and an increased understanding of how humans
make decisions (see generally Kahneman, Thinking Fast
and Slow (Kahneman 2011) and the identification of the
“cognitive biases” (unconscious distortions in reasoningthat affect the rationality of decision making) it seems in-
creasingly understood that the neutralization, quantifica-
tion of data and examination through neutral mechanisms
will greatly increase the correct decisions in any system,
but especially in those that are extremely data laden and
complex, like health and patient care.
Nonetheless, companion diagnostics and software, data
analytics and other information technology advancements
all have the potential to create a significant commercial
benefit in markets with pricing flexibility in terms of
market share, but are likely to be of higher value for later-
to-market entrants. This is due to the fact that companion
diagnostics and corresponding theranostic assays divide
the market of treatable patients into groups and clusters,
thus reducing market share. A companion drug, however,
that is capable of identifying a group of patients that
responds to a specific therapy very well, enables higher
pricing and thus generates value to stakeholders. In this
regard, the key is the payer’s price sensitivity that varies a
lot by disease area; therefore, drug classes can be seg-
mented according to their scientific and commercial
potential.
Pharmaceutical companies may be more likely to
invest in diagnostics and technologies that impact larger
groups, generally such as those in areas like infectious
diseases, immunology and oncology, with the latter
being the most advanced field for personalized medicine.
The segmentation also reveals disease areas where
incentives are not aligned to drive investment, despite
technical feasibility and clinical need; among them are
antipsychotics or anticoagulants. Firms focusing on
diagnostic tests provide a huge variety of different
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in cancer medicine, early-stage diagnostics, susceptibility
tests for adverse or toxic side-effects of drugs, genomic
tests for risk assessments of a particular inherited dis-
ease as well as tests that include companion diagnostics.
Amid the excitement and attention paid to personalized
cancer treatment, it is crucial to remember that other
conditions like psychiatric disorders carry as great a soci-
etal burden, yet remain too poorly understood to benefit.
From an economic view, revenue generation with
diagnostic tests remains challenging; albeit diagnostic
tests influence most clinical decision-making, they only
account for a small percentage of today’s health insurance
expenditures.
However, P4 medicine indeed has a great potential to
catalyze changes in the increasing costs of medical care
and will ultimately result in reduced costs to the point
where P4 medicine will be exported to the developing
world; as such, P4 medicine will be the foundation of
global health care in the future. The reduction of costs
will be achieved through a variety of factors, among
them is the digitalization of health care and advances in
health care IT, novel translational technologies such as
next-generation sequencing technologies entering clinical
laboratories, and the emerging field of single-cell omics
that allow the analysis of thousands of cells in a high
throughput manner (Hood and Galas 2003). The central
challenge of modern medicine is the stratification of
patients, e.g. based on novel biomarkers, and the classi-
fication of patients into subgroups with different combi-
nations of disease-perturbed networks (Ivshina 2006).
Crucially, the adoption of the P4 concept will enable the
focus of medicine to shift from disease to wellness, with
enormous attendant cost savings to society resulting in
a lower requirement for sick leave and a concurrent
increase in productivity. Furthermore, many factors will
converge to bring the costs of health care down in a
striking manner so that the benefits of P4 medicine can
be shared by rich and poor nations alike.
Molecular diagnostics
Molecular diagnostics are a very attractive market
segment to target due to the potential for significantly
higher prices and gross margins. Companies like Myriad,
Genomic Health or PathGen Diagnostics have developed
innovative molecular diagnostics despite the risk that
comes along with such developments in terms of develop-
ment, approval, rates of provider adoption, sales prices
or time-to-payer coverage. Since these risks are often
underestimated, the (micro-) economics of molecular
diagnostic companies that launched products vary
significantly. The most important factors in this market
are the rate of payer adoption and the time that is
needed for approval. In terms of approval by the FDA, a510 (k) approval may be sufficient for diagnostics that
are prognostic indicators. Though, if a test directly influ-
ences clinical decision-making to go for a specific therapy,
the FDA very likely will ask for a premarket approval that
further increases the time to market significantly. In the
present market and regulatory environment, molecular
diagnostic companies therefore face challenging econom-
ics. However, as personalized medicine is progressing and
evolving fast, more diagnostic tests will become available
with developers, clinicians, patients, regulators and payers
gaining more experience in this field. This in turn will
likely influence and speed up the approval processes, and
introduce better transparency.
As molecular diagnostics data begin to accumulate
from next-generation sequencing / whole-genome sequen-
cing efforts, for instance from tumor samples, disease clas-
sifications are likely to become even more precise and be
extended into more diverse cancer types. Here, P4 medi-
cine will clearly provide the technical and computational
tools for more accurate patient stratifications. The devel-
opments in the molecular diagnostic sector will directly
impact clinical trial structures and patient recruitments
and will therefore induce a fundamental change in the
business plans of the pharmaceutical industry.
From an economics perspective, the main mediators
for personalized and private medicine are investments
by biotech and pharmaceutical industries, which should
take a long-term view on such investments. There is a
trend towards outcome- and value-based pricing and re-
imbursement models in many countries and this greatly
increases the financial value of P4 medicine, and particu-
larly the incentives to invest in it. For reimbursement
models, innovative strategies are required. For instance,
reimbursements could depend on patient outcomes or
risk-sharing models for drug and diagnostic coverage.
The first step towards such healthcare systems is, however,
that regulatory institutions improve both efficiency and
clarity of approval processes for drugs and companion
diagnostics. Also, the regulations allowing personalized
medicine-based diagnostic test results to guide therapeutic
interventions and therapy planning must be defined.
Diagnostics and theranostics firms should demonstrate
their willingness to comply with novel guidelines and
even help shaping them – as a result they might justify
higher prices due to the approval processes. From the
authorities, however, stringent and fast approval pro-
cesses are required, thus avoiding any negative impact
on investments in the development of novel diagnostics
and therapeutics. Examples would be a guideline that
clinical data on marker-negative patients are not neces-
sarily required, thus saving costs on the development
side, or to allow the approval of companion diagnostics
on the basis of retrospective trials of a novel diagnostic
marker on, for instance, paraffin-embedded formalin-
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treatments of a patient unnecessary and thus, physicians
often have a higher interest in performing procedures
rather than diagnostic tests.
The P4 approach will be successful for all parties
involved: patients receive better care and physicians gain
valuable information about the molecular characteristics
of their patients’ diseases. The challenge is now to get
P4 medicine into reality. Consequently, outcome-based
approaches for reimbursement and joint approaches by
payers and diagnostic firms will enable a faster adoption
of personalized medicine-based diagnostics and thus
improve the overall process and transparency of cover-
age decisions.Review, Conclusions
The developments in genomic technologies and near real-
time access to medical records will enable the creation of
more and more truly personalized medicine-based diag-
nostic tests and system-wide efficiencies in health care. To
make P4 medicine a standard in clinical practice, all stake-
holders should closely collaborate to reshape the incen-
tives in personalized medicines and thus provide a basis
for better and more efficient patient treatments and care
pathways. Health systems reforms that promote a more
flexible and value-based reimbursement for innovative
diagnostics and therapeutics are critical to create stronger
economic incentives for the development of personalized
medicine and better care to patients.
P4 medicine will catalyze a transformation of standard
care that promises to deal with the heretofore-impenetrable
barriers of complexities of disease pathways through sys-
tems approaches, emerging technologies and powerful
genome analytical tools. The promise is that the focus of
medicine will be shifted from disease to wellness and that
thousands of data points for each individual patient will
be taken into account and define with exquisite specificity
the nature of their wellness and any transitions into
disease. Central to this view is the idea that the molecular,
cellular, genomic and phenotypic data of eventually thou-
sands of patients will be available for complex systems
analyses, i.e. integration, normalizing, query, mining, ana-
lysis, storage and protection of data. This will catalyze the
development of predictive and actionable models. The
availability of these data will be necessary to exploit the
infinite potential of the P4 medicine of the future.
The scientific, economic, and also the societal barriers
for these objectives are considerable; overcoming the
hurdles will require new ways for scientists to engage
with each other, new relations between patients, scien-
tists, and industry and, finally, will require new strategic
partnerships among all stakeholders in the personalized
medicine field.Consent
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